TY - JOUR AU - Hu, Ning AU - Cheng, Zhiheng AU - Pang, Yifan AU - Zhao, Hongmian AU - Ding, Hui AU - Chen, Li AU - Li, Qianyu AU - Han, Yu AU - Qin, Tong AU - Dai, Yifeng AU - Zhang, Yijie AU - Shi, Jinlong AU - Wu, Depei AU - Fu, Lin PY - 2019 TI - Prognostic effect of allogeneic hematopoietic stem cell transplantation on first and non-first complete remission in acute myeloid leukemia JF - Annals of Translational Medicine; Vol 7, No 18 (September 30, 2019): Annals of Translational Medicine Y2 - 2019 KW - N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the cure for intermediate or adverse-risk acute myeloid leukemia (AML) (1). It offers patients longer overall survival (OS) (2-4). Unfortunately, human leukocyte antigen (HLA) matched related donor is unavailable in more than 70% patients. Some of these patients, may experience relapse and subsequently achieve CR (non-CR1) with treatment. Some non-CR1 patients eventually receive allo-HSCT. It is unclear whether allo-HSCT will improve the survival of these patients. UR - https://atm.amegroups.org/article/view/29076